François Jenck
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
François Jenck has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
Jean-Luc Moreau
Central Nervous System Research, Roche Pharma Division, CH4070 Basel, Switzerland; and ‡CeNes Ltd., Compass House, Vision Park, Histon, Cambridge CB4 4ZR, United Kingdom
4 shared publicationsJames R. Martin
Central Nervous System Research, Roche Pharma Division, CH4070 Basel, Switzerland; and ‡CeNes Ltd., Compass House, Vision Park, Histon, Cambridge CB4 4ZR, United Kingdom
3 shared publications- Jean-Luc Moreau
Pharma Division, Preclinical CNS Research, F. Hoffmann-La Roche, PRPN, 72/141, CH-4070, Basel, Switzerland
2 shared publications A M Ouagazzal
1 shared publicationAbdel M. Ouagazzal
Central Nervous System Research, Roche Pharma Division, CH4070 Basel, Switzerland; and ‡CeNes Ltd., Compass House, Vision Park, Histon, Cambridge CB4 4ZR, United Kingdom
1 shared publicationAndrea M. Cesura
Central Nervous System Research, Roche Pharma Division, CH4070 Basel, Switzerland; and ‡CeNes Ltd., Compass House, Vision Park, Histon, Cambridge CB4 4ZR, United Kingdom
1 shared publication
Latest Publications
- 1 January 2001
- Published by Taylor & Francis in Journal of Receptors and Signal Transduction
- Vol. 21 (1) , 55-70
IMPROVED SEMLIKI FOREST VIRUS VECTORS FOR RECEPTOR RESEARCH AND GENE THERAPY
We have modified Semliki Forest virus (SFV) vectors to broaden their application range. Here we describe a series of site-directed mutagenesis experiments on the SFV subgenomic 26S promoter to down-regulate the heterologous gene expression. Several mutants showed a dramatic effect on transgene expression levels in BHK cells. The luciferase activity was reduced to approximately 30%, 3%, and 1% compared to the wild type promoter. Similarly, a decrease in beta-galactosidase activity was observed in BHK cells and after injection into the striatum of male Wistar rats. Novel non-cytopathogenic and temperature-sensitive SFV vectors have recently been developed by introduction of point mutations in the viral nonstructural genes nsP2 and nsP4. These vectors do not show the typical shut down of host cell protein synthesis after SFV infections and therefore allow for a substantially prolonged survival of host cells. Both the mutant vectors demonstrating lower and more physiological expression levels and the non-cytopathogenic vectors should be valuable tools for various applications within receptor research. Furthermore, recent studies suggest that SFV vectors can be efficient gene delivery vehicles for gene therapy applications.
- 1 January 2001
- Published by Taylor & Francis in Journal of Receptors and Signal Transduction
- Vol. 21 (1) , 55-70
IMPROVED SEMLIKI FOREST VIRUS VECTORS FOR RECEPTOR RESEARCH AND GENE THERAPY
We have modified Semliki Forest virus (SFV) vectors to broaden their application range. Here we describe a series of site-directed mutagenesis experiments on the SFV subgenomic 26S promoter to down-regulate the heterologous gene expression. Several mutants showed a dramatic effect on transgene expression levels in BHK cells. The luciferase activity was reduced to approximately 30%, 3%, and 1% compared to the wild type promoter. Similarly, a decrease in beta-galactosidase activity was observed in BHK cells and after injection into the striatum of male Wistar rats. Novel non-cytopathogenic and temperature-sensitive SFV vectors have recently been developed by introduction of point mutations in the viral nonstructural genes nsP2 and nsP4. These vectors do not show the typical shut down of host cell protein synthesis after SFV infections and therefore allow for a substantially prolonged survival of host cells. Both the mutant vectors demonstrating lower and more physiological expression levels and the non-cytopathogenic vectors should be valuable tools for various applications within receptor research. Furthermore, recent studies suggest that SFV vectors can be efficient gene delivery vehicles for gene therapy applications.
- 1 November 2000
- Published by Springer Nature in Molecular Psychiatry
- Vol. 5 (6) , 572-574
OrphaninFQ: role in behavioral fear responses and vulnerability to stress?
- 1 November 2000
- Published by Springer Nature in Molecular Psychiatry
- Vol. 5 (6) , 572-574
OrphaninFQ: role in behavioral fear responses and vulnerability to stress?
- Open Access
- 11 April 2000
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 97 (9) , 4938-4943
A synthetic agonist at the orphanin FQ/nociceptin receptor ORL1: Anxiolytic profile in the rat
The biochemical and behavioral effects of a nonpeptidic, selective, and brain-penetrant agonist at the ORL1 receptor are reported herein. This low molecular weight compound {(1 S ,3a S )-8- (2,3,3a,4,5,6-hexahydro-1 H -phenalen-1-yl)-1-phenyl-1,3,8-triaza- spiro[4.5]decan-4-one} has high affinity for recombinant human ORL1 receptors and has 100-fold selectivity for ORL1 over other members of the opioid receptor family. It is a full agonist at these receptors and elicits dose-dependent anxiolytic-like effects in a set of validated models of distinct types of anxiety states in the rat (i.e., elevated plus-maze, fear-potentiated startle, and operant conflict). When given systemically, the compound has an efficacy and potency comparable to those of a benzodiazepine anxiolytic such as alprazolam or diazepam. However, this compound is differentiated from a classical benzodiazepine anxiolytic by a lack of efficient anti-panic-like activity, absence of anticonvulsant properties, and lack of effects on motor performance and cognitive function at anxiolytic doses (0.3 to 3 mg/kg i.p.). No significant change in intracranial self-stimulation performance and pain reactivity was observed in this dose range. Higher doses of this compound (≥10 mg/kg) induced disruption in rat behavior. These data confirm the notable anxiolytic-like effects observed at low doses with the orphanin FQ/nociceptin neuropeptide given locally into the brain and support a role for orphanin FQ/nociceptin in adaptive behavioral fear responses to stress.
- 11 April 2000
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 97 (9) , 4938-4943
Open AccessA synthetic agonist at the orphanin FQ/nociceptin receptor ORL1: Anxiolytic profile in the rat
The biochemical and behavioral effects of a nonpeptidic, selective, and brain-penetrant agonist at the ORL1 receptor are reported herein. This low molecular weight compound {(1 S ,3a S )-8- (2,3,3a,4,5,6-hexahydro-1 H -phenalen-1-yl)-1-phenyl-1,3,8-triaza- spiro[4.5]decan-4-one} has high affinity for recombinant human ORL1 receptors and has 100-fold selectivity for ORL1 over other members of the opioid receptor family. It is a full agonist at these receptors and elicits dose-dependent anxiolytic-like effects in a set of validated models of distinct types of anxiety states in the rat (i.e., elevated plus-maze, fear-potentiated startle, and operant conflict). When given systemically, the compound has an efficacy and potency comparable to those of a benzodiazepine anxiolytic such as alprazolam or diazepam. However, this compound is differentiated from a classical benzodiazepine anxiolytic by a lack of efficient anti-panic-like activity, absence of anticonvulsant properties, and lack of effects on motor performance and cognitive function at anxiolytic doses (0.3 to 3 mg/kg i.p.). No significant change in intracranial self-stimulation performance and pain reactivity was observed in this dose range. Higher doses of this compound (≥10 mg/kg) induced disruption in rat behavior. These data confirm the notable anxiolytic-like effects observed at low doses with the orphanin FQ/nociceptin neuropeptide given locally into the brain and support a role for orphanin FQ/nociceptin in adaptive behavioral fear responses to stress.
- 1 March 1999
- Published by SAGE Publications in Journal of Psychopharmacology
- Vol. 13 (2) , 166-170
The 5-HTlA receptor agonist flesinoxan increases aversion in a model of panic-like anxiety in rats
Acute systemic administration of the selective serotonin (5-HT)lA receptor full agonist fiesinoxan enhanced the sensitivity of rats to the panic-like aversion elicited by local stimulation of the dorsolateral periaqueductal grey (dPAG). This experimental paradigm in rats has previously been validated as a simulation of acute anxiety with particular relevance to panic disorder. The dose-dependent decrease in threshold for acute fear responses recorded in rats following intraperitoneal administration of flesinoxan (1-10mg/kg) was similar to that induced by the panic precipitating agent yohimbine and opposite to the threshold increase induced by the antipanic drug alprazolam. The proaversive effect of flesinoxan observed in rats is consistent with the reported aggravation of the condition of panic patients following oral flesinoxan treatment. Thus, the model adequately detects drug-induced panicogenic-like properties. Data suggest that selective activation of 5-HTIA receptors (preand/or post-synaptic in brain and/or periphery) following systemic administration of 5-HTIA receptor full agonists exacerbates aversion in animals or patients with panic anxiety; activation of these receptor subtypes may probably mediate the panicogenic action reported under certain circumstances with non-selective 5-HT mimetics.
- 1 March 1999
- Published by SAGE Publications in Journal of Psychopharmacology
- Vol. 13 (2) , 166-170
The 5-HTlA receptor agonist flesinoxan increases aversion in a model of panic-like anxiety in rats
Acute systemic administration of the selective serotonin (5-HT)lA receptor full agonist fiesinoxan enhanced the sensitivity of rats to the panic-like aversion elicited by local stimulation of the dorsolateral periaqueductal grey (dPAG). This experimental paradigm in rats has previously been validated as a simulation of acute anxiety with particular relevance to panic disorder. The dose-dependent decrease in threshold for acute fear responses recorded in rats following intraperitoneal administration of flesinoxan (1-10mg/kg) was similar to that induced by the panic precipitating agent yohimbine and opposite to the threshold increase induced by the antipanic drug alprazolam. The proaversive effect of flesinoxan observed in rats is consistent with the reported aggravation of the condition of panic patients following oral flesinoxan treatment. Thus, the model adequately detects drug-induced panicogenic-like properties. Data suggest that selective activation of 5-HTIA receptors (preand/or post-synaptic in brain and/or periphery) following systemic administration of 5-HTIA receptor full agonists exacerbates aversion in animals or patients with panic anxiety; activation of these receptor subtypes may probably mediate the panicogenic action reported under certain circumstances with non-selective 5-HT mimetics.
- 1 August 1998
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 8 (3) , 161-168
Antiaversive effects of 5HT2C receptor agonists and fluoxetine in a model of panic-like anxiety in rats
- 1 August 1998
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 8 (3) , 161-168
Antiaversive effects of 5HT2C receptor agonists and fluoxetine in a model of panic-like anxiety in rats
- 1 November 1996
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 6 (4) , 291-298
Behavioral effects of CCKB receptor ligands in a validated simulation of panic anxiety in rats
- 1 November 1996
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 6 (4) , 291-298
Behavioral effects of CCKB receptor ligands in a validated simulation of panic anxiety in rats
- 1 December 1993
- Published by Elsevier in Pharmacology Biochemistry and Behavior
- Vol. 46 (4) , 905-910
Acute and chronic administration of buspirone fails to yield anxiolytic-like effects in a mouse operant punishment paradigm
- 1 December 1993
- Published by Elsevier in Pharmacology Biochemistry and Behavior
- Vol. 46 (4) , 905-910
Acute and chronic administration of buspirone fails to yield anxiolytic-like effects in a mouse operant punishment paradigm
- 1 January 1993
- Published by Georg Thieme Verlag KG in Pharmacopsychiatry
- Vol. 26 (01) , 30-33
Effects of Moclobemide, a New Generation Reversible Mao-A Inhibitor, in a Novel Animal Model of Depression
This study was designed to investigate the predictive validity of a recently described chronic mild-stressinduced anhedonia model of depression. In an intracranial self-stimulation (ICSS) paradigm, rats were allowed to selfstimulate in the ventral tegmental area. Stimulation frequency thresholds for ICSS responses were determined prior to, during, and after a 19-day period of exposure to a variety of mild, intermittent, unpredictable stressors. After nine days of mild stress, stimulation threshold was significantly increased, suggesting a gradual decrease in the rewarding properties of brain stimulation. This anhedonic state lasted throughout the stress period and slowly disappeared over a 10-day period after termination of the stress regimen. This stress-induced increase in ICSS threshold was not observed in rats that were stressed and concomitantly treated with the reversible inhibitor of monoamine oxidase type A (RIMA) moclobemide (20 mg / kg, b.i.d.). In nonstressed animals treated with vehicle or moclobemide, no significant change in ICSS occurred during the course of the experiment. These experimental results reinforce the value of this animal model with respect to its predictive and construct validity. Diese Studie prüft die prognostische Gültigkeit eines neuen Depressionsmodells, das auf einer durch wiederholten, milden Streß erzeugten Anhedonia beruht. In einem Hirn-Selbstreizungs-Paradigma konnten sich Ratten über eine Elektrode im ventralen Tegmentum elektrisch stimulieren. Die Frequenzschwellen wurden vor, während und nach einer 19 tägigen Periode gemessen, in der die Ratten verschiedenen kurzen, milden und unvorhergesehenen Streßbedingungen ausgesetzt wurden. Nach 9 Tagen milder Streßexposition war die Reizschwelle signifikant erhöht, was auf eine graduelle Abschwächung der Belohnungseigenschaften der Hirnreizung hindeutet. Dieser anhedonische Zustand dauerte während der ganzen Streßperiode und verschwand danach langsam während der nachfolgenden 10 Tage. Diese Streß-induzierte Reizschwellenerhöhung trat nicht auf, wenn die Tiere gleichzeitig mit dem reversiblen Monoaminoxidase-Hemmer des Typs A (RIMA) Moclobemid (20 mg / kg bid) behandelt wurden. Bei nicht gestreßten Tieren bewirkte Moclobemid keine signifikante Veränderung der Hirnselbstreizungsschwelle. Diese Versuchsergebnisse untermauern den Nutzen dieses Tiermodells im Hinblick auf seinen prognostischen Wert und seine Relevanz für die Depression.
- 1 January 1993
- Published by Georg Thieme Verlag KG in Pharmacopsychiatry
- Vol. 26 (01) , 30-33
Effects of Moclobemide, a New Generation Reversible Mao-A Inhibitor, in a Novel Animal Model of Depression
This study was designed to investigate the predictive validity of a recently described chronic mild-stressinduced anhedonia model of depression. In an intracranial self-stimulation (ICSS) paradigm, rats were allowed to selfstimulate in the ventral tegmental area. Stimulation frequency thresholds for ICSS responses were determined prior to, during, and after a 19-day period of exposure to a variety of mild, intermittent, unpredictable stressors. After nine days of mild stress, stimulation threshold was significantly increased, suggesting a gradual decrease in the rewarding properties of brain stimulation. This anhedonic state lasted throughout the stress period and slowly disappeared over a 10-day period after termination of the stress regimen. This stress-induced increase in ICSS threshold was not observed in rats that were stressed and concomitantly treated with the reversible inhibitor of monoamine oxidase type A (RIMA) moclobemide (20 mg / kg, b.i.d.). In nonstressed animals treated with vehicle or moclobemide, no significant change in ICSS occurred during the course of the experiment. These experimental results reinforce the value of this animal model with respect to its predictive and construct validity. Diese Studie prüft die prognostische Gültigkeit eines neuen Depressionsmodells, das auf einer durch wiederholten, milden Streß erzeugten Anhedonia beruht. In einem Hirn-Selbstreizungs-Paradigma konnten sich Ratten über eine Elektrode im ventralen Tegmentum elektrisch stimulieren. Die Frequenzschwellen wurden vor, während und nach einer 19 tägigen Periode gemessen, in der die Ratten verschiedenen kurzen, milden und unvorhergesehenen Streßbedingungen ausgesetzt wurden. Nach 9 Tagen milder Streßexposition war die Reizschwelle signifikant erhöht, was auf eine graduelle Abschwächung der Belohnungseigenschaften der Hirnreizung hindeutet. Dieser anhedonische Zustand dauerte während der ganzen Streßperiode und verschwand danach langsam während der nachfolgenden 10 Tage. Diese Streß-induzierte Reizschwellenerhöhung trat nicht auf, wenn die Tiere gleichzeitig mit dem reversiblen Monoaminoxidase-Hemmer des Typs A (RIMA) Moclobemid (20 mg / kg bid) behandelt wurden. Bei nicht gestreßten Tieren bewirkte Moclobemid keine signifikante Veränderung der Hirnselbstreizungsschwelle. Diese Versuchsergebnisse untermauern den Nutzen dieses Tiermodells im Hinblick auf seinen prognostischen Wert und seine Relevanz für die Depression.
- 1 January 1992
- Vol. 47, 379-94
Partial agonists of benzodiazepine receptors for the treatment of epilepsy, sleep, and anxiety disorders.
The classic benzodiazepines produce anxiolytic, anticonvulsant, sedative and myorelaxant effects at overlapping dose ranges. Efforts to reduce the sedative/myorelaxant component of this profile has a long history. Two rational approaches might theoretically lead to the desired drugs. One is based on the combination of partial (low efficacy) agonists of the benzodiazepine receptor with different receptor reserves in neurons subversing various functions. The other approach is based on the existence of GABAA-benzodiazepine receptor polymorphism and assumes that distinct receptor variants may be more prevalent on neurons involved in various CNS functions. Results are presented that were obtained with the partial agonist bretazenil and three other ligands in vitro as well as in vivo. Curves relating fractional receptor occupancy and various effects (potentiation of GABA-induced chloride flux, anticonvulsant, anticonflict and sedative effects) are fully consistent with the view that the particular profile of activity of bretazenil is the result of partial agonism. Comparison of fractional receptor occupancy required for the various effects of both full and partial agonists confirm earlier suggestions that receptor reserves for the individual effects differ with the same order. Clinical aspects of partial benzodiazepine receptor agonists are discussed on the basis of the preliminary information available to date.
- 1 January 1992
- Vol. 47, 379-94
Partial agonists of benzodiazepine receptors for the treatment of epilepsy, sleep, and anxiety disorders.
The classic benzodiazepines produce anxiolytic, anticonvulsant, sedative and myorelaxant effects at overlapping dose ranges. Efforts to reduce the sedative/myorelaxant component of this profile has a long history. Two rational approaches might theoretically lead to the desired drugs. One is based on the combination of partial (low efficacy) agonists of the benzodiazepine receptor with different receptor reserves in neurons subversing various functions. The other approach is based on the existence of GABAA-benzodiazepine receptor polymorphism and assumes that distinct receptor variants may be more prevalent on neurons involved in various CNS functions. Results are presented that were obtained with the partial agonist bretazenil and three other ligands in vitro as well as in vivo. Curves relating fractional receptor occupancy and various effects (potentiation of GABA-induced chloride flux, anticonvulsant, anticonflict and sedative effects) are fully consistent with the view that the particular profile of activity of bretazenil is the result of partial agonism. Comparison of fractional receptor occupancy required for the various effects of both full and partial agonists confirm earlier suggestions that receptor reserves for the individual effects differ with the same order. Clinical aspects of partial benzodiazepine receptor agonists are discussed on the basis of the preliminary information available to date.